Intellia Therapeutics Inc Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 87.81. In total, the insiders bought 1 676 490 and sold 102 679 NTLA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
87.81
Buy 1 676 490 Shares
Sell 102 679 Shares

Historical Insider Trades

Date Type Action Person Amount
Jul 01, 2024 Common Stock Sell Clark Eliana 405
Jul 01, 2024 Common Stock Buy Dube Michael P 17 801
Jun 17, 2024 Common Stock Sell Verwiel Frank 1 505
Jun 13, 2024 Buy Goff Brian 0
Jun 13, 2024 Stock Option (right to buy) Buy Goff Brian 22 297
Jun 13, 2024 Common Stock Buy Goff Brian 15 409
Jun 12, 2024 Common Stock Buy Verwiel Frank 7 737
Jun 12, 2024 Stock Option (right to buy) Buy Verwiel Frank 11 515
Jun 12, 2024 Common Stock Buy Keresty Georgia 7 737
Jun 12, 2024 Stock Option (right to buy) Buy Keresty Georgia 11 515
Jun 12, 2024 Common Stock Buy Goodman Jesse 7 737
Jun 12, 2024 Stock Option (right to buy) Buy Goodman Jesse 11 515
Jun 12, 2024 Common Stock Buy Cohen Fred E 7 737
Jun 12, 2024 Stock Option (right to buy) Buy Cohen Fred E 11 515
Jun 12, 2024 Common Stock Buy Bhanji Muna 7 737
Jun 12, 2024 Stock Option (right to buy) Buy Bhanji Muna 11 515
Jun 12, 2024 Common Stock Buy Chase William J 7 737
Jun 12, 2024 Stock Option (right to buy) Buy Chase William J 11 515
Apr 10, 2024 Common Stock Buy Dube Michael P 0
Mar 04, 2024 Common Stock Sell Basta James 2 297
Mar 04, 2024 Common Stock Sell Clark Eliana 605
Mar 01, 2024 Common Stock Buy Sepp-lorenzino Laura 37 966
Mar 01, 2024 Stock Option (right to buy) Buy Sepp-lorenzino Laura 54 794
Mar 01, 2024 Common Stock Buy Basta James 32 394
Mar 01, 2024 Stock Option (right to buy) Buy Basta James 46 752
Click to get the best stock tips daily for free!

About Intellia Therapeutics Inc

Intellia Therapeutics Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline... NTLA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT